CLINE B Stock Overview
A life science company, develops cancer diagnostics and stem cell therapies in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cline Scientific AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.07 |
| 52 Week High | SEK 0.28 |
| 52 Week Low | SEK 0.06 |
| Beta | 0.41 |
| 11 Month Change | -11.84% |
| 3 Month Change | -49.82% |
| 1 Year Change | -72.66% |
| 33 Year Change | -98.16% |
| 5 Year Change | -97.85% |
| Change since IPO | -98.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLINE B | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -5.1% | -4.3% | -4.3% |
| 1Y | -72.7% | 48.5% | 12.6% |
Return vs Industry: CLINE B underperformed the Swedish Life Sciences industry which returned 47.5% over the past year.
Return vs Market: CLINE B underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
| CLINE B volatility | |
|---|---|
| CLINE B Average Weekly Movement | 26.3% |
| Life Sciences Industry Average Movement | 8.3% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: CLINE B's share price has been volatile over the past 3 months.
Volatility Over Time: CLINE B's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 2 | Anders Sundh | www.clinescientific.com |
Cline Scientific AB (publ), a life science company, develops cancer diagnostics and stem cell therapies in Sweden. The company’s clinical-stage projects include StemCART, a stem cell therapy for joint repair; and CellRACE, a cancer diagnostic to predict metastasis. It also develops nanotechnology based products for work within Life Sciences.
Cline Scientific AB (publ) Fundamentals Summary
| CLINE B fundamental statistics | |
|---|---|
| Market cap | SEK 3.15m |
| Earnings (TTM) | -SEK 3.15m |
| Revenue (TTM) | SEK 4.20m |
0.8x
P/S Ratio-1.0x
P/E RatioIs CLINE B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLINE B income statement (TTM) | |
|---|---|
| Revenue | SEK 4.20m |
| Cost of Revenue | SEK 95.81k |
| Gross Profit | SEK 4.10m |
| Other Expenses | SEK 7.25m |
| Earnings | -SEK 3.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.07 |
| Gross Margin | 97.72% |
| Net Profit Margin | -74.95% |
| Debt/Equity Ratio | 4.0% |
How did CLINE B perform over the long term?
See historical performance and comparison